Healthcare Services

Dermatomycoses Market Growth Supported by Rising Fungal Infections

April 21, 2026April 21, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Dermatomycoses Market Between 2026 And 2030?

Significant expansion has been observed in the dermatomycoses market size over recent years. It is projected to increase from $14.81 billion in 2025 to $15.59 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.3%. The market’s historical growth is attributable to factors such as humid climate exposure, poor hygiene conditions, a reliance on topical drugs, limited awareness, and hospital-based treatment.

The dermatomycoses market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $19.11 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.2%. Factors contributing to this growth during the forecast period include advancements in antifungal formulations, a rise in the occurrence of skin infections, an increase in outpatient care services, enhanced awareness regarding hygiene, and the broader availability of dermatology services. Key trends expected over the forecast period encompass an escalating prevalence of fungal skin infections, a greater adoption of topical antifungals, the development of combination antifungal treatments, the widening scope of outpatient dermatology care, and an emphasis on preventing recurrence.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/dermatomycoses-global-market-report

What Factors Are Contributing To The Growth Of The Dermatomycoses Market?

The increasing incidence of fungal infections is projected to fuel the expansion of the dermatomycoses market in the future. Fungal infections are conditions caused by fungi that target the skin, nails, hair, or internal organs, leading to various health complications. The excessive use of broad-spectrum antibiotics disrupts the natural microbiome, creating an environment conducive for fungi to grow and cause infections. This imbalance weakens the body’s inherent defense mechanisms, rendering individuals more prone to opportunistic fungal infections. Dermatomycoses, which are fungal diseases triggered by dermatophytes, yeasts, and molds, affect various tissues and manifest as common superficial and systemic infections. For instance, in November 2023, the UK Health Security Agency reported global estimates indicating an annual incidence of 6.5 million invasive fungal infections, resulting in approximately 3.8 million deaths, with 2.5 million directly attributed to these infections. Therefore, the growing prevalence of fungal infections is a significant driver for the dermatomycoses market.

Which Segment Classifications Are Used In The Dermatomycoses Market Segment Analysis?

The dermatomycoses market covered in this report is segmented –

1) By Drugs: Corticosteroids, Corticosteroid-Sparing Agents, Immunosuppressive, Immunomodulator, Antifungals, Other Drugs

2) By Route Of Administration: Oral, Parenteral, Topical, Other Routes Of Administrations

3) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids

2) By Corticosteroid-Sparing Agents: Tacrolimus, Pimecrolimus

3) By Immunosuppressive: Methotrexate, Azathioprine, Cyclophosphamide

4) By Immunomodulator: Interferon-Gamma, Thalidomide

5) By Antifungals: Topical Antifungals, Oral Antifungals, Systemic Antifungals

6) By Other Drugs: Antihistamines, Antibacterial Agents

What Trends Are Shaping The Future Of The Dermatomycoses Market?

Leading companies in the dermatomycoses market are concentrating on investigational new drug candidates to advance onychomycosis treatment and enhance efficacy. An investigational new drug (IND) candidate refers to a pharmaceutical compound undergoing preclinical or clinical trials to assess its safety, effectiveness, and potential for regulatory approval before it becomes an approved treatment. For instance, in January 2024, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the US Food and Drug Administration (FDA), a US-based government agency, for its Investigational New Drug VTR-297 candidate designed for onychomycosis treatment. VTR-297 distinguishes itself as a topical antifungal candidate due to its histone deacetylase (HDAC) inhibitor properties, setting it apart from traditional antifungal remedies. This agent functions by targeting the core reason for fungal growth, demonstrating powerful antifungal activity against dermatophytes and other fungi. This innovative mode of action has the capacity to deliver quicker and more impactful treatment results, simultaneously lessening the chance of infection recurrence, thereby addressing a significant unmet demand in onychomycosis therapy.

Which Firms Are Contributing To The Dermatomycoses Market Ecosystem?

Major companies operating in the dermatomycoses market are Pfizer Inc., Bayer AG, Saphnix Life Sciences, MITS Healthcare Private Limited, Weefsel Pharma, AdvaCare Pharma, Associated Biotech, Healthy Life Pharma Private Limited, Blueberry Therapeutics Ltd., Livealth Biopharma Pvt. Ltd., LGM Pharma, SiNi Pharma Pvt. Ltd., Joshi Agrochem Pharma Private Limited, Wellona Pharma, Abiba Pharmacia Pvt. Ltd., Vee Excel Drugs & Pharmaceuticals Pvt. Ltd., Femcorp Pharma, Lexicare Pharma Pvt. Ltd., Glamris Dermacare, Henin Lukinz

Get The Full Dermatomycoses Market Report:

https://www.thebusinessresearchcompany.com/report/dermatomycoses-global-market-report

Which Region Is The Largest In The Dermatomycoses Market?

North America was the largest region in the dermatomycoses market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dermatomycoses market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Dermatomycoses Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/dermatomycoses-global-market-report

Browse Through More Reports Similar to the Global Dermatomycoses Market 2026, By The Business Research Company

Onychomycosis Market Report 2026

https://www.thebusinessresearchcompany.com/report/onychomycosis-global-market-report

Dermatitis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Veterinary Dermatology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-dermatology-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795